S5 E4: Interview with Prof Miriam Santer on BMJ Spironolactone for acne in GP; physician associates; once-weekly insulin; tirzepatide vs insulin for T2DM | NB Medical
 

S5 E4: Interview with Prof Miriam Santer on BMJ Spironolactone for acne in GP; physician associates; once-weekly insulin; tirzepatide vs insulin for T2DM

NO
PHARMACEUTICAL INFLUENCE
NO PHARMACEUTICAL INFLUENCE
10th November 2023

If you are having difficulties listening to this Podcast, try to play this episode in Spotify

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. The highlight of this episode is our interview with Prof Miriam Santer, lead author of recent research in the BMJ exploring the effectiveness of spironolactone for acne in women.

Does it work? Is it a treatment for general practice? And if so, is it safe, what monitoring is required, and where does it fit with current acne pathways?

In the news, we think about the current issues around physician associates in general practice. In research we have two papers on diabetes: first, in the Lancet, is a new once-weekly insulin injection as effective as a daily treatment for type 1 diabetes; and second, in JAMA, is the additional tirzepatide better than prandial insulin in addition to glargine for managing type 2 diabetes?

References

Eczema Care Online

BMJ Spiro for acne

Lancet Once weekly insulin vs daily insulin in T1DM

JAMA Tirzepatide vs prandial insulin in T2DM


Join us at one of our upcoming courses or live webinars